The discovery of cell-free tumor and fetal DNA molecules in the plasma of cancer patients
and pregnant women, respectively, has opened up exciting opportunities in molecular …

Circulating cell-free DNA (cfDNA) has been suggested as a cancer biomarker. Several
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …

Cancer is a common cause of death worldwide. Despite significant advances in cancer
treatments, the morbidity and mortality are still enormous. Tumor heterogeneity, especially …

Background: To verify whether the concentrations and integrity index of circulating cell-free
DNA (ccf-DNA) in serum may be clinically useful for the diagnosis and progression …

The increasing knowledge of the molecular pathogenesis of cancer and the rapid
development of new molecular techniques are promoting the study of early molecular …

Nucleosomes, complexes of DNA and histone proteins, are released from dying and
stressed cells into the blood circulation. Concentrations of circulating nucleosomes in …

Cell-free DNA (cfDNA) has pioneered the development of noninvasive prenatal testing and
liquid biopsy, its emerging applications include organ transplantation, autoimmune …

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from
human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and …

Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …

Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-
invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount …